Zimmer Biomet (NYSE:ZBH) Given New $113.00 Price Target at Wells Fargo & Company

Zimmer Biomet (NYSE:ZBH) had its target price boosted by research analysts at Wells Fargo & Company from $103.00 to $113.00 in a research note issued to investors on Thursday, Benzinga reports. The firm presently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price target would indicate a potential upside of 3.02% from the stock’s previous close.

Other equities analysts also recently issued research reports about the company. Sanford C. Bernstein boosted their target price on Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Royal Bank Of Canada lifted their price target on Zimmer Biomet from $101.00 to $110.00 and gave the stock an “outperform” rating in a report on Thursday, August 6th. Citigroup reissued a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, October 5th. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research note on Wednesday, August 5th. Finally, Robert W. Baird set a $104.00 price target on shares of Zimmer Biomet in a report on Thursday, August 6th. Seven analysts have rated the stock with a Buy rating, sixteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus target price of $106.89.

Zimmer Biomet Stock Down 0.4%

Shares of ZBH stock traded down $0.46 on Thursday, hitting $109.69. The stock had a trading volume of 364,791 shares, compared to its average volume of 2,250,515. The business has a 50 day moving average of $94.90 and a 200 day moving average of $91.89. The stock has a market cap of $20.92 billion, a price-to-earnings ratio of 26.64, a price-to-earnings-growth ratio of 2.33 and a beta of 0.50. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94. Zimmer Biomet has a 12-month low of $79.12 and a 12-month high of $112.54.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The business had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2.04 billion. During the same period in the previous year, the company earned $1.90 earnings per share. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. As a group, analysts expect that Zimmer Biomet will post 8.54 EPS for the current year.

Insider Buying and Selling at Zimmer Biomet

In other news, insider Chad Phipps sold 3,000 shares of the stock in a transaction on Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. This represents a 4.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total value of $528,978.45. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Zimmer Biomet

Several large investors have recently modified their holdings of ZBH. BlackRock Inc. purchased a new stake in shares of Zimmer Biomet during the 2nd quarter valued at approximately $1,344,282,000. State Street Corp grew its stake in Zimmer Biomet by 0.6% in the 2nd quarter. State Street Corp now owns 8,877,171 shares of the medical equipment provider’s stock valued at $766,343,000 after buying an additional 52,044 shares in the last quarter. Primecap Management Co. CA purchased a new position in Zimmer Biomet in the 2nd quarter valued at approximately $328,578,000. Dimensional Fund Advisors LP raised its holdings in Zimmer Biomet by 1.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,224,163 shares of the medical equipment provider’s stock valued at $201,082,000 after acquiring an additional 24,208 shares during the period. Finally, Bank of America Corp DE bought a new stake in Zimmer Biomet during the 2nd quarter valued at $187,480,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet News Summary

Here are the key news stories impacting Zimmer Biomet this week:

• Positive Sentiment: Third-quarter sales were $2.063 billion, up 3.1% year over year (3.7% at constant currency), topping estimates of $2.04 billion. Adjusted diluted EPS of $1.90 also exceeded consensus, while the company raised its full-year 2026 financial guidance. These results and the improved outlook are key supports for the shares. Zimmer Biomet Announces Third Quarter 2026 Financial Results
• Positive Sentiment: Hip and S.E.T. sales helped counter a challenging knee market. The CEO also said the company is not seeing a slowdown in orthopedic procedures, offering reassurance on underlying demand. Zimmer Biomet Q3 2026: How Diversification Offset a Weak Knee Quarter Zimmer Biomet CEO doesn’t see slowdown in ortho procedures
• Negative Sentiment: Reported diluted EPS fell 13.8% to $1.00, while adjusted EPS of $1.90 was unchanged from a year earlier. Knee weakness and margin pressure temper the positive sales and guidance news. Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.